LEADER 01008nam0-22003371i-450- 001 990007163650403321 005 20121019123710.0 010 $a88-13-22929-1 035 $a000716365 035 $aFED01000716365 035 $a(Aleph)000716365FED01 035 $a000716365 100 $a20021021d2001----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $a<>delitti dei pubblici ufficiali nell'attivitą amministrativa$fIvone Cacciavillani, Carmelo Renato Calderone 210 $aPadova$cCedam$d2001 215 $aXIX , 223 p.$d24 cm 676 $a342$v20$zita 700 1$aCacciavillani,$bIvone$0230025 701 1$aCalderone,$bCarmelo Renato$0263060 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007163650403321 952 $aXI A 127$b4486$fDDCIC 952 $a5,1-495$b3491$fDSPCP 959 $aDDCIC 959 $aDSPCP 996 $aDelitti dei pubblici ufficiali nell'attivitą amministrativa$9690043 997 $aUNINA LEADER 01521nam 2200421Ia 450 001 9910696923303321 005 20230902161803.0 035 $a(CKB)5470000002383662 035 $a(OCoLC)558588044 035 $a(EXLCZ)995470000002383662 100 $a20100318d2009 ua 0 101 0 $aeng 135 $auran||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aGuidance for industry$b[electronic resource] $eassay development for immunogenicity testing of therapeutic proteins 210 1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :$cCenter for Biologics Evaluation and Research,$d[2009] 215 $a1 online resource (20 pages) $cillustrations 300 $a"Draft guidance." 300 $a"CMC." 300 $a"December 2009." 320 $aIncludes bibliographical references (pages 19-20). 517 $aGuidance for industry 606 $aImmunogenetics$zUnited States 606 $aBiological assay 606 $aProteins$xTherapeutic use$xTesting 615 0$aImmunogenetics 615 0$aBiological assay. 615 0$aProteins$xTherapeutic use$xTesting. 712 02$aCenter for Drug Evaluation and Research (U.S.) 712 02$aCenter for Biologics Evaluation and Research (U.S.) 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910696923303321 996 $aGuidance for industry$93434577 997 $aUNINA